Экспрессия ангиогенных факторов при раке яичников III-IV стадии
Диссертация
Экспрессия маркеров, связанных с ангиогенезом, была также оценена на эндотелиальных клетках микрососудов опухоли. VEGF на эндотелиальных клетках был обнаружен в 62,5% случаев рака яичников. При этом он прямо коррелировал с экспрессией VEGF в опухолевых клетках (к=0,24, р=0,021). Экспрессия bFGF на эндотелиальных клетках составила — 26%, и также прямо ассоциировалась с экспрессией bFGF… Читать ещё >
Содержание
- Список сокращений
Глава 1. Обзор литературы 8 Механизмы опухолевого неоангиогенеза. Особенности процессов неоангиогенеза рака яичников.
Глава 2. Материалы и методы исследования
Глава 3. Экспрессия ангиогенных факторов при раке яични- 42 ков
Глава 4. Клиническое значение ангиогенных факторов при 71 раке яичников
Список литературы
- Барышников А.Ю., Степанова Е. В., Личиницер М. Р. Оценка ангиогенеза опухолей человека. Успехи современной биологии. 2000. Том. 120. № 6. С. 599−604.
- Карамышева А.Ф. Ангиогенез опухоли: механизмы, новые подходы. // в книге Канцерогенез. Под редакцией Д. Г. Заридзе. Москва, Научный мир 2000.
- Копнин Б.П. Неопластическая клетка: основные свойства и механизмы их возникновения. // Практическая онкология 2002- 3(4): 229−235.
- Степанова Е.В., Барышников А. Ю. Молекулярно-биологические маркеры рака яичников. Сборник статей, приуроченный к Европейской школе по онкологии, посвященной раку яичников, Москва 2001.
- Степанова Е.В. Антиангиогенная терапия: новые возможности лечения злокачественных заболеваний. // Практическая онкология 2002- 3(4): 246−252.
- Bouck N, Stellmach V., Hsu SC. How tumors become angiogenic. // Adv Cancer Res 1996, 69: 135−174.
- Folkman J. Tumor angiogenesis. In Cancer Medicine, JF. Holland, RC. Bast, DL. Morton, E. Frei, DW. Kufe, RR. Weichselbaum, eds. // (Baltimore, MD: Williams and Wilkins). 1997: 181−204.
- Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic swich during tumorigenesis.// Cell, 86:353−364,1996.
- Folkman J.: Tumor angiogenesis: therapeutic implications. // N. Eng. J. Med, 1971- 285- 1182−1186.
- Liotta L. A, Kleinerman J., Saidel G.M.: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. // Cancer Res, 1974- 34- 997−1004.
- Folkman J.: What is the evidence that tumors are angiogenesis dependent? // J. Natl. Inst, 1990- 82- 4−6.
- Srivastava A., Laidler P., et al.: The prognostic significance of tumor vascularity in intermediate-thickness (0.76−4.0 mm thick) skin melanoma. A quantitative histologic study. //Am. J. Pathol. 1988- 133- 419−423.
- Starkey J.R., Crowle P.K., et al.: Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. // Int. J. Cancer, 1988, 42- 48−52
- Bicknell R. Mechanistic insights into tumour angiogenesis. // in book Tumour Angiogenesis. Edited by Roy Bicknell. Oxford University Press. 1997.
- Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. // Nature Med. 6,389−395 (2000).
- Ellis L.M. Tumor Angiogenesis. // Horizons in Cancer Res. 2002- 3(1): 4 -22.
- Holash J., Wiegand SJ., Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoetins and VEGF. // Oncogene., 1999- 18:5356−5362.
- Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific*growth factors and blood vessel formation. // Nature 2000 407: 242−248.
- Chistofalli M., Charnsangavej C. and. Hortobagyi G.N. Angiogenesis modulation in cancer research: novel clinical approaches. // Nature Reviews. 2002- 1:415−426.
- Bikfalvi A., Klein S., Pintucci G., Rifkin D. The role of proteases in angiogenesis. // in book Tumour Angiogenesis. Edited by Roy Bicknell. Oxford University Press. 1997.
- Hiraoka N., et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. // Cell 1998- 91: 365−377.
- McCawley LJ., Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. // Mol Medicine Today. 2000- 6: 149 156.23. www.angio.org/providers/oncology/oncology.html
- Shweiki D, Itin A, Neufeld G, Gitay-Goren H, and Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. // J Clin Invest 91: 2235−2243, 1993.
- Shweiki D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. // Nature 359: 843−845, 1992.
- Ferrara N., Henzel W.J.: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. // Biochem. Bio-phys. Res. Commun, 1989- 161- 851−858.
- Park JE., Keller G-A., Ferrara N. the vascular endothelial growth factor (VEGF) isoforms: differantioal deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGF. // Mol. Biol. Cell., 1993- 4: 13 171 326.
- Singer D.R., Perruzzi C.A., et al.: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. // Cancer Res., 1986- 46, 5629−5632.
- Tolentino M.J., Miller J.W., Gragoudas E.S., et al.: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. // Arch. Ophthalmol., 1996- 114- 964−970.
- Cao Y., Linden P., Farnebo J., et al.: Vascular endothelial growth factor С induces angiogenesis in vivo. // Proc. Natl. Acad. Sci. USA, 1998- 95- 1 438 914 394
- Senger D.R., Perruzzi C.A., et al.: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. // Cancer Res, 1986- 46, 5629−5632.
- Alon T, Hemo I, Itin A, et al.: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy ofpermaturity.//Nat. Med, 1995- 1- 1024−1028
- Shweiki D, Itin A, Soffer D, et al.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. // Nature, 1992- 359- 843−845.
- Minchenko A, Bauer T, Salceda S, et al.: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. // Lab. Invest, 1994- 71- 374−379.
- Neufeld G, Cohen T, Gengrinovitch S, et al.: Vascular endothelial growth factor (VEGF) and its receptors. // FASEB J, 1999- 13- 9−22.
- Liu B, Earl H. M, Baban D, et al.: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. // Biochem. Biophys. Res. Commun, 1995- 217- 721−727.
- Boocock CA, Charnock-Jones S, Sharkey AM, McLaren J, Baker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. // J Natl Cancer Inst 1995, 87:506−516
- Ferrarra N, Davis-Smith T. The biology of vascular growth factor. // Endocrinol. Reviews, 1997- 18 (1): 4−25.
- Alitalo K, Korpelainen E. Signaling angiogenesis and lymphangiogene-sis. // Current Opinion in Cell Biology 1998- 10:159−164.
- Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y. The fourth immunoglobulin domain of the Stem Cell Factor receptor couples ligand binding to signal transduction. // Cell, 1995- 80: 103−113.
- Sam Mesiano, Napoleone Ferrara, Robert B. Jaffe: Role of Vascular Endothelial Growth Factor in Ovarian Cancer. H American Journal of Pathology, Vol. 153,1998- 1249−1256.
- Yuan HT, Yang SP, Woolf AS Hypoxia up-regulates angiopoietin-2, a Tie-2 ligand, in mouse mesangial cells. // Kidney Int 2000- 58:5 1912−9.
- Olson ТА, Mohanraj D, Carson LF, Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. // Cancer Res 1994, 54:276−280
- Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, LF, Ramakrishnan S: Vascular endothelial growth factor expression early stage ovarian carcinoma. // Cancer 1997, 80:98−106
- Stromberg K, Johnson GR, O’Connor DM, Sorensen CM, Gullick WJ, Kannan B: Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. // Int J Gynecol Pathol 1994, 13:342−347
- Carter WB, Ward MD. HER2 regulatory control of angiopoietin-2 in breast cancer. // Surgery 2000- 128:2 153−8.
- Kutteh WH, Kutteh CC: Quantitation of tumor necrosis factor-alpha, in-terleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms. // Am J Obstet Gynecol 1992, 167:1864−1869
- Yamamoto S, I Konishi, et al: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathol-ogy and patient survival, and analysis of serum VEGF levels. // Cancer Res. 1997, 76:1221−1227.
- Christine A. Boocock, D. Stephen Charnock-Jones, et al: Expression of vascular endothelial growth factor and its receptors fit and KDR in Ovarian Carcinoma. // J. of the National Cancer Institute 1995, 87:506−516.
- Tsuyoshi Etoh, Hiroshi Inoue, Shinji Tanaka, Graham F. Barnard, Seigo Kitano, and Masaki Mori. Angiopoietin-2 Is Related to Tumor Angiogenesis in
- Gastric Carcinoma: Possible in Vivo Regulation via Induction of Proteases. // Cancer Res 2001,61:2145−2153.
- Davis, S, and Yancopoulos, G. D. The angiopoietins: Yin and Yang in angiogenesis. // Curr. Top. Microbiol. Immunol, 237: 173−185, 1999.
- Dumont, D. J, Yamaguchi, Т. P, Conlon, R. A, Rossant, J, and Breit-man, M. L. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed endothelial cells and their presumptive precursors. // Oncogene, 7: 1471−1480, 1992.
- Hanahan, D. Signaling vascular morphogenesis and maintenance. //Science (Washington DC), 277: 48−50, 1997.
- Qin Yu and Ivan Stamenkovic. Angiopoietin-2 Is Implicated in the Regulation of Tumor Angiogenesis.//American Journal of Pathology, Vol. 158, No. 2, February 2001, 563−570
- Koblizek TL, Weiss C, Yancopoulos GD, Deutsch U, Risau W: Angio-poietin-1 induces sprouting angiogenesis in vitro. // Curr Biol 1998, 8:529−532
- Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM: Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie 2. // J Biol Chem 1998, 273:18 514−18 521
- Volpert OV, ZaichukT, ZhouW, ReiherF, Ferguson ТА, Stuart PM, Amin M, Bouck NP. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. // Nat Med 2002- 8: 349−357.
- Stratmann A, Risau W, Plate KH: Cell-type specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. // Am J Pathol 1998, 153:1459−1466.
- Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan ТЕ, Bruno J, Radziejewski C, Maisonpierre P, Yancopoulos GD: Isolation of angiopoietin-1, a ligand for the tie2 receptor, by secretiontrap expression cloning.//Cell 1996, 87:1161−1169.
- Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG: Tie2 expression, and phosphorylation in angiogenic, and quiescent adult tissues. // С ire Res 1997, 81:567−574.
- Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E: Expression of Tie2/Tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis. // Br J Cancer 1998, 77:51−56
- Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the tie2 receptor, during embryonic angiogenesis. // Cell 1996, 87:1171−1180.
- Koblizek TL, Weiss C, Yancopoulos GD, Deutsch U, Risau W: Angio-poietin-1 induces sprouting angiogenesis in vitro. // Curr Biol 1998, 8:529−532.
- Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. //Adv. Cancer res. 1992- 59: 115−165.
- Klein S., Giancotti FG, Presta M., Aldelda SA, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates intrgrin expression in microvascular endothelial cells. // Mol. Biol. Cell., 1993- 4:973−982.
- Nguyen M., Watanabe H., Budson AE., Richie JP., Hayes DF., Folkman J. Elevated levels of angiogenic peptide basic fibriblast growth factor in the murine of patients with a wide spectrum of cancers. // J. Natl. Cancer Inst. 1994- 86:356−361.
- Ishitsuka H., Miwa M., Ishikawa Т., et al.: Capecitabine: an orally available fluoropyrimidine with tumor selectivity. // Proc. Am. Assoc. Cancer Res., 1995- 36- 2426.
- Sumizawa Т., Fukukawa Т., Haraguchi M., et al.: Thymidine phosphory-lase activity associated with platelet-derived endothelial cell growth factor. // J. Biochem, 1993- 114: 9−14.
- Furukawa T, Yoshimura A, Sumizawa Т., et al.: Angiogenic factor. // Nature, 1992- 356: 668.
- Takebayashi Y, Yamada K, Maruyama I, et al.: The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. //Cancer Lett, 1995- 25- 1−7.
- Fujimoto J, Ichigo S, Sakaguchi H, Hirose R, Tamaya T: Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers. // Cancer Lett 1998 Apr 10−126(l):83−8.
- Fujiwaki R, Hata K, Nakayama K, Fukumoto M, Miyazaki K. Thymidy-late synthase expression in epithelial ovarian cancer: relationship withthymidine phosphorylase expression and prognosis. // Oncology 2000 Aug- 59(2): 152−7.
- Stevenson DP, Collins WP, Farzaneh F, Hata K, Miyazaki K. Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer. // Am J Pathol 1998 Nov-153(5):1573−8.
- Matsumoto Y, et al: Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms.//Int J Mol Med 2001:8:31−36.
- Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. // Am J Pathol 2002 Mar- 160(3):893−903.
- Soslow RA, et al: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. // Cancer 2000:89:2637−2645.
- Tsuji M, DuBois RN: Alterations in cellular adhesion and apoptosis inepithelial cells overexpressing prostaglandin endoperoxide synthase 2. //1. Cell 1995,83:493−501.
- Tsuji M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. // Cell 1998, 93:705−716.
- Tsuji M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. // Proc Natl Acad Sci USA 1997, 94:3336−3340.
- Tomozawa S, et al: Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis of colorectal cancer. // Br J Cancer 2000- 83:324−328.
- Madaan S, et al: Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. // Br J Urol 2000- 86:736−741.
- Hwang D, et al: Expression of cyclooxygenase-1 of cyclooxygenase-2 in human breast cancer. // J Natl Cancer Inst 1999- 90:455−460.
- Tuker ON, et al: Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. // Cancer Res 1999:59:987−990.
- Denkret C, et al: Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. //Am J Pathol- 160: 893−903.
- Nasi ML, Castiglione M. Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled? //Ann Oncol 2002- 13(8): 1169−1171.
- Sumi T, Ishiko O, Yoshida H, Hyun Y, Nakagawa E, Hirai K, Matsu-moto Y, Ogita S. Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. // Int J Mol Med 2001- 8(5):495−498.
- Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP, Saed GM. Effects of prostaglandin E (2) on proliferation and apoptosis of epithelial ovarian cancer cells. // J Soc Gynecol Investig 2002 May-Jun-9 (3):168−73.
- Folkman J. Angiogenesis inhibitors generated by tumors. // Mol. Med. Physiol. 1991- 1: 120−122.
- Tolsma S., Volpert O., Good D., Frazier W., Polverini P., Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. //J.Cell Biol. 1993. V.122. P.497.
- Fraizier W., Prater C., Jaye D., Kosfeld M. // Thrombospondin. 1994. P.91.
- Wight T. N, Raugi G. J, Mumby S, Bornstein P. Light microscopic immunolocation of thrombospondin in human tissues. // J. Histochem. Cyto-chem. 1985. V.33.P.295.
- Wong S. Y, Purdie A. T, Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohis-tochemical study. // Amer. J. Pathol. 1992. V.140. P. 1473.
- Roberts D. D, Sherwood J. A, Ginsburg V. Platelet thrombospondin mediates attachment and spreading of human melanoma cells. // J. Cell Biol. 1987. V.104. P. 131.
- Varani J, Dixit V. M, Fligel S. E, McKeever P. E, Carey Т.Е. Throm-bospondin-induced attachment and spreading of human squamous carcinoma cells. // Exper. Cell Res. 1986. V.105. P.376.
- Tuszynski G. P, Gasic T. B, Rothman V. L, Knudsen K. A, Gasic G.J. Thrombospondin, a potentiator of tumor cell metastasis. // Cancer Res. 1987. V.47. P.4130.
- Zabrenetzky V, Harris C, Steeg P, Roberts D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. // Internat. J. Cancer. 1994. V.59.P.191.
- Castle V. P, Ou X, O’Rourke K, Dixit V. High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum- and anchorage-independent growth. //J.Biol.Chem. 1993- 268: 2899.
- Castle V. P, Varani J, Fligiel S, Prochownik E. V, Dixit V. // J. Clin. Invest. 1991. V.87. P. 1883.
- Tuszynski G. P, Gasic T. B, Rothman V. L, Knudsen K. A, Gasic G.J. Thrombospondin, a potentiator of tumor cell metastasis. // Cancer Res. 1987. V.47. P.4130.
- Pratt D. A, Miller W. R, Dawes J. Thrombospondin in malignant and non-malignant breast tissue. //Europ. J. Cancer Clin. Oncol. 1989. V.25. P.343.
- Kodama J, Hashimoto I, Seki N, Hongo A, Yoshinouchi M, OkudaH, Kudo T. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. // Anticancer Res 2001 Jul-Aug- 21(4B): 2983−7
- OReilly M.S., et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. //Cell.9, 315−328.
- OReilly M.S., et al. Endostatin: an endogeneous inhibitor of angiogenesis and tumor growth. // Cell.88, 277−285.
- Yumi Yokoyama, Mohanraj D., Arjan W., et al: Synergy between Angiostatin and Endostatin: Inhibition of Ovarian Cancer Growth. // Cancer Res. 2000, 60,2190−2196.
- Steeg P. S., Bevilacqua G., Kopper L., et al.: Evidence for a novel gene associated with low tumor metastatic potential. // J. Natl. Cancer Inst., 1988- 80- 200−204.
- Backer J.M., Mendola C.E., Kovesdi I., et al.: Chromosomal localization and nucleoside diphosphate kinase activity in human metastasis-suppressor genes NM23−1 and NM23−2. // Oncogene, 1993- 8- 497−502.
- Leone A., Seeger R.C., Hong C.M., et al.: Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas./ Oncogene, 1993- 8- 855−865.
- Caligo M.A., Cipollini G., Fiore L., et al.: NM23 gene expression correlates with cell growth rate and S-phase. // Int. J. Cancer, 1995- 60- 837−842.
- Lombardi D., Sacchi D., d’Angostino G., et al.: The association of the Nm23-Ml protein and beta-tubulin correlates with cell differenciation. // Exp. Cell Res., 1995- 217- 267−271.
- Howlett A. R, Petersen O. W, Steeg P. S., et al.: A novel function for the nm23-Hl gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. //J. Natl. Cancer Inst, 1994- 86- 1838−1844
- Barnes R, Masood S, Barker E, et al.: Low nm23-protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. // Amer. J. Path, 1991- 139- 245−250.
- Royds J. A, Stephenson T. J, Rees R. C, et al.: Nm23 protein expression in ductal in situ and invasive human breast carcinoma. //J. Nat. Cancer Inst, 1993- 85- 727−731.
- Qian M, Feng Y, Xu L, Zheng S, Zhou X Expression of antimetastatic gene nm23-Hl in epithelial ovarian cancer. // Chin Med J (Engl) 1997 Feb 110:142−4
- Simone G, Falco G, Caponio MA, Campobasso C, De Frenza M, Petroni S, Wiesel S, Leone A. nm23 expression in malignant ascitic effusions of serous ovarian adenocarcinoma. // Int J Oncol 2001 Nov Yumi Yokoyama -19 (5):885−90
- TasF, Tuzlali S, AydinerA, SaipP, Salihoglu Y, IplikciA, TopuzE Prognostic role of nm23 gene expression in patients with ovarian cancer. // Am J Clin Oncol 2002 Apr 25:164−7
- Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. // Nature Reviews. 2002- 2: 727−739.
- Dameron, K. M, Volpert, O. V, Tainsky, M. A, and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. // Science 1994, 265, 1582- 1584.
- Adolf, K. W, Liska, D. J, and Bornstein, P. // (1997) Gene, 193, 5−11.
- Mukhopadhyay, D, Tsiokas, L, and Sukhatme, V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. //CancerRes 1995, 55, 6161−6165.
- Graeber, T. G, Osmanian, C, Jacks, T, Housman, D. E, Koch, C. J, Lowe, S, and Giaccia, A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. //Nature 1996, 379, 88−91.
- Volpert, O. V, Dameron, K. M, and Bouck, N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. //Oncogene 1997, 14, 1495−1502.
- Grugel, S, Finkenzeller, G, Weindel, K, Barleon, B, and Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. // J Biol Chem, 1995, Oct 27, 270:43, 25 915−9
- Saez, E, Rutberg, S. E, Mueller, E, Oppenheim, H, Smoluk, J, Yuspa, S. H, and Spiegelman, B.M. c-fos is required for malignant progression of skin tumors. // Cell 1995, Sep 8 82:5, 721−732.
- Meade-Tollin, L.C., Boukamp, P., Fusenig, N.E., Bowen, C.P., Tsang, T.C., and Bowden G.T. Differential expression of matrix metalloproteinases in activated c-ras-Ha-transfected immortalized human keratinocytes. // Br J Cancer 1998 Mar 77:5 724−30.
- Giambernardi, T.A., Grant, G.M., Taylor, G.P., Hay, R.J., Maher, V.M., McCormick, J.J., and Klebe, R.J. // (1998) Matrix Biol., 16, 483−496.
- Himelstein, B.P., Lee, E.J., Sato, H., Seiki, M., and Muschel, R.J. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. // Oncogene 1997 Apr 24 14:16 1995−8.
- Newberry, E.P., Willis, D., Latifi, Т., Boudreaux, J.M., and Towler, D.A. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-APl element. //Mol Endocrinol 1997 Jul 11:8 1129−44.
- Christofori G., and Hanahan, D. Molecular dissection of multi-stage tumorigenesis in transgenic mice // Semin Cancer Biol 1994, Feb 5:1,3−12.
- Richards, F.M., Webster, A.R., McMahon, R., Woodward, E.R., Rose, S., and Maher, E.R. Molecular genetic analysis of von Hippel-Lindau disease. // J Intern Med 1998, Jun 243:6,527−33.
- Wizigmann-Voos, S., Breier, G., Risau, W., and Plate, K.H. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. // Cancer Res 1995, Mar 15, 55:6, 1358−64.
- Seimeister, G., Weindel, K., Mohrs, K., Barleon, В., Martiny-Baron, G., and Marme, D. // Cancer Res. 1996, 56, 2299−2301.
- Moghaddam A., Choudhuri R., Bicknell R. Thymidine phosphory-lase/platelet-derived endothelial cell growth factor: an angiogenic enzyme. // in book Tumour Angiogenesis. Edited by Roy Bicknell. Oxford University Press. 1997.
- Dempke W, Rie C, Grothey A, Schmoll H-J. Cyclooxigenase-2: a novel target for cancer chemotherapy? // J. Cancer Res. Clin. Oncol. 2001- 127: 411−417.
- Cristofori G. The role of fibroblast growth factors in tumour progression and angiogenesis. // in book Tumour Angiogenesis. Edited by Roy Bick-nell. Oxford University Press. 1997.
- De Jong JS, Van Diest PJ, Van der Valk P., Baak JPA. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I and II. // J. Pathol. 1998- 184: 44−52, 53−57.
- Biancone L., De Martino A, Orlandi V, Conaldi PG, Toniolo A., Ca-mussi G. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. // J. Exp. Med. 1997- 1: 147−152.